Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 Abril 2024 - 3:00PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced an upcoming poster
presentation at the American Society of Clinical Oncology (ASCO)
annual meeting taking place May 31-June 4 in Chicago. The details
are as follows:
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in
patients (pts) with advanced solid tumors treated with less
frequent intravenous (IV) dosing (ARTISTRY-3)
Session: Developmental Therapeutics – Immunotherapy
Date and time: June 1, 2024, 9 a.m. CDT
Abstract #: 2587
Speaker/lead author: Sarina Piha-Paul, MD
The poster will be available at muraloncology.com/publications
following the presentation.
About Nemvaleukin
Nemvaleukin alfa (nemvaleukin) is a novel, engineered cytokine
designed to leverage antitumor effects of the IL-2 pathway while
mitigating its hallmark toxicities that limit its use. Nemvaleukin
selectively binds to the intermediate-affinity IL-2 receptor
(IL-2R) and is sterically occluded from binding to the
high-affinity IL-2R. Because of this molecular design, nemvaleukin
treatment leads to preferential expansion of antitumor CD8+ T cells
and natural killer cells, with minimal expansion of
immunosuppressive regulatory T cells. Nemvaleukin is currently
being evaluated in two potentially registrational trials in
platinum resistant ovarian cancer and mucosal melanoma.
A newly recommended phase 2 dose of nemvaleukin (infusions on
days 1 and 8 per three-week dosing cycle) will be explored in
monotherapy and in combination with pembrolizumab in patients with
cutaneous melanoma as part of the ARTISTRY-6 trial.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering
platform to develop cytokine-based immunotherapies for the
treatment of cancer. By combining our expertise in cytokine biology
and immune cell modulation and our protein engineering platform, we
are developing medicines to deliver meaningful and clinical
benefits to people living with cancer. Our mission is to
broaden the potential and reach of cytokine-based immunotherapies
to improve the lives of patients. Our lead candidate, nemvaleukin,
is currently in potentially registrational trials in mucosal
melanoma and platinum-resistant ovarian cancer. Mural Oncology has
its registered office in Dublin, Ireland, and its primary
facilities in Waltham, Mass. For more information, visit Mural
Oncology’s website at www.muraloncology.com and follow us on
LinkedIn and X.
Investors:David Borah,
CFAdavid.borah@muraloncology.com781-614-0060
Media:Katie
Sullivankatie.sullivan@muraloncology.com
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De May 2023 a May 2024